Minsheng Securities released a research report on April 9 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a recommended rating. The main reasons for the rating include: 1) the rapid expansion of CDMO business for APIs and formulations, and a steady increase in project revenue during the commercialization phase; 2) layout of specialty platforms for peptides, conjugated drugs, and small nucleic acids to successfully complete multiple project delivery tasks; 3) comprehensively improving advanced production capacity for APIs, CDMOs, peptides and formulations, and continuously strengthening global business acceptance capabilities. (Mainichi Keizai Shimbun)
民生证券4月9日发布研报称，给予九洲药业（603456.SH）推荐评级。评级理由主要包括：1）原料药、制剂CDMO业务快速拓展，商业化阶段项目收入稳步提升；2）布局多肽与偶联药物、小核酸特色平台，成功完成多个项目交付工作；3）全面提升原料药、CDMO、多肽和制剂先进产能，持续强化全球化业务承接能力。（每日经济新闻）
Minsheng Securities released a research report on April 9 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a recommended rating. The main reasons for the rating include: 1) the rapid expansion of CDMO business for APIs and formulations, and a stead
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated